留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

NALP3炎症体与胰岛素抵抗的研究进展

梁微微 李乃适 潘慧

梁微微, 李乃适, 潘慧. NALP3炎症体与胰岛素抵抗的研究进展[J]. 协和医学杂志, 2015, 6(5): 372-375. doi: 10.3969/j.issn.1674-9081.2015.05.012
引用本文: 梁微微, 李乃适, 潘慧. NALP3炎症体与胰岛素抵抗的研究进展[J]. 协和医学杂志, 2015, 6(5): 372-375. doi: 10.3969/j.issn.1674-9081.2015.05.012

NALP3炎症体与胰岛素抵抗的研究进展

doi: 10.3969/j.issn.1674-9081.2015.05.012
详细信息
    通讯作者:

    潘慧 电话:010-69156114, E-mail:panhui20111111@163.com

  • 中图分类号: R587.1

  • [1] Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome[J]. Lancet, 2005, 365:1415-1428. doi:  10.1016/S0140-6736(05)66378-7
    [2] Tschopp J, Martinon F, Burns K. NALPs:a novel protein family involved in inflammation[J]. Nat Rev Mol Cell Biol, 2003, 4:95-104. doi:  10.1038/nrm1019
    [3] Fritz JH, Ferrero RL, Philpott DJ, et al. Nod-like proteins in immunity, inflammation and disease[J]. Nat Immunol, 2006, 7:1250-1257. doi:  10.1038/ni1412
    [4] Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes[J]. Nat Rev Immunol, 2013, 13:397-411. doi:  10.1038/nri3452
    [5] Zhou R, Tardivel A, Thorens B, et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation[J]. Nat Immunol, 2010, 11:136-140. doi:  10.1038/ni.1831
    [6] Kanneganti TD, Dixit VD. Immunological complications of obesity[J]. Nat Immunol, 2012, 13:707-712. doi:  10.1038/ni.2343
    [7] Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease[J]. Nat Rev Immunol, 2011, 11:98-107. doi:  10.1038/nri2925
    [8] Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases[J]. Nat Rev Immunol, 2008, 8:923-934. doi:  10.1038/nri2449
    [9] Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance[J]. Nat Med, 2011, 17:179-188. doi:  10.1038/nm.2279
    [10] Wen H, Gris D, Lei Y, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling[J]. Nat Immunol, 2011, 12:408-415. doi:  10.1038/ni.2022
    [11] Stienstra R, Joosten LAB, Koenen T, et al. The Inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity[J]. Cell Metab, 2010, 12:593-605. doi:  10.1016/j.cmet.2010.11.011
    [12] Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes[J]. Nat Immunol, 2010, 11:897-904. doi:  10.1038/ni.1935
    [13] Koenen TB, Stienstra R, van Tits LJ, et al. Hyperglycemia activates caspase-1 and TXNIP-mediated IL-1 beta transcription in human adipose tissue[J]. Diabetes, 2011, 60:517-524. doi:  10.2337/db10-0266
    [14] Jager J, Gremeaux T, Cormont M, et al. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression[J]. Endocrinology, 2007, 148:241-251. doi:  10.1210/en.2006-0692
    [15] Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes:results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study[J]. Diabetes, 2003, 52:812-817. doi:  10.2337/diabetes.52.3.812
    [16] Malozowski S, Sahlroot JT. Interleukin-1-receptor antagonist in type 2 diabetes mellitus[J]. N Engl J Med, 2007, 357:302-303. doi:  10.1056/NEJMc071324
    [17] Akash MS, Shen Q, Rehman K, et al. Interleukin-1 receptor antagonist:a new therapy for type 2 diabetes mellitus[J]. J Pharm Sci, 2012, 101:1647-1658. doi:  10.1002/jps.23057
    [18] Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen:a phase IIb randomized, placebo-controlled trial[J]. Circulation, 2012, 126:2739-2748. doi:  10.1161/CIRCULATIONAHA.112.122556
    [19] Cavelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes[J]. Diabetes Care, 2012, 35:1654-1662. doi:  10.2337/dc11-2219
    [20] Sloan-Lancaster J, Abu-Raddad E, Polzer J, et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes[J]. Diabetes Care, 2013, 36:2239-2246. doi:  10.2337/dc12-1835
    [21] Rotter V, Nagaev I, Smith U. Interleukin-6(IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects[J]. J Biol Chem, 2003, 278:45777-45784. doi:  10.1074/jbc.M301977200
    [22] Senn JJ, Klover PJ, Nowak IA, et al. Interleukin-6 induces cellular insulin resistance in hepatocytes[J]. Diabetes, 2002, 51:3391-3399. doi:  10.2337/diabetes.51.12.3391
    [23] Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3(SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes[J]. J Biol Chem, 2003, 278:13740-13746. doi:  10.1074/jbc.M210689200
    [24] Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss[J]. J Clin Endocrinol Metab, 2000, 85:3338-3342. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=5217e7a390c760f0d19146061dd825f9
    [25] Wang X, Bao W, Liu J, et al. Inflammatory markers and risk of type 2 diabetes:a systematic review and meta-analysis[J]. Diabetes Care, 2013, 36:166-175. doi:  10.2337/dc12-0702
    [26] Hotamisligil GS, Budavari A, Murray D, et al. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha[J]. J Clin Invest, 1994, 94:1543-1549. doi:  10.1172/JCI117495
    [27] Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase[J]. J Clin Invest, 1995, 95:2111-2119. doi:  10.1172/JCI117899
    [28] Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year[J]. Circulation, 2002, 105:804-809. doi:  10.1161/hc0702.104279
    [29] Hivert MF, Sullivan LM, Fox CS, et al. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance[J]. J Clin Endocrinol Metab, 2008, 93:3165-3172. doi:  10.1210/jc.2008-0425
    [30] Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization[J]. J Clin Invest, 2007, 117:175-184. doi:  10.1172/JCI29881
    [31] Lee HM, Kim JJ, Kim HJ, et al. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes[J]. Diabetes, 2013, 62:194-204. doi:  10.2337/db12-0420
    [32] Zheng Y, Zhang D, Zhang L, et al. Variants of NLRP3 gene are associated with insulin resistance in Chinese Han population with type-2 diabetes[J]. Gene, 2013, 530:151-154. doi:  10.1016/j.gene.2013.07.082
    [33] Dehghan A, Dupuis J, Barbalic M, et al. Meta-analysis of genome-wide association studies in > 80000 subjects identifies multiple loci for C-reactive protein levels[J]. Circulation, 2011, 123:731-738. doi:  10.1161/CIRCULATIONAHA.110.948570
    [34] Lamkanfi M, Mueller JL, Vitari AC, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome[J]. J Cell Biol, 2009, 187:61-70. doi:  10.1083/jcb.200903124
  • 加载中
计量
  • 文章访问数:  145
  • HTML全文浏览量:  55
  • PDF下载量:  6
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-07-19
  • 刊出日期:  2015-09-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!